Ascentage Pharma Group International

NASDAQ:AAPG

Biotechnology

Healthcare
$13.01 +1.78%

+$0.31 today

Market cap
$1.21B
Beta
0.65
P/E (TTM)
-8.9
EPS (TTM)
-$13.29
52W Low $16.92High $48.45

Volume 0.00M

Average 0.01M

AAPG Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Ascentage Pharma Group InternationalNASDAQ: AAPG

Selling, General & Admin · Q4 FY2025 · quarter ended Dec 2025

Selling, general & admin grows 54.4% year over year

Q4 FY2025 selling, general & admin of CN¥318.79M rose 54.4% year over year. Over 3 fiscal years it compounded at +16.8% a year.

Context

  • Selling, general & admin amounted to 93.6% of revenue in FY2025, up 54.5 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 7 analysts of CN¥1.78B (+239.9%) for the fiscal year ending Dec 2026, a step up from the +36.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
CN¥318.79M— QoQ
Last fiscal yearDec 2025
CN¥522.67M+36.4% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+54.4%——
1 year+36.4%+239.9%+203.5 pp
3-year CAGR+16.8%+125.5%+108.7 pp
5-year CAGR+101.5%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

CNY · from the income statement

Latest · FY2025
522.67M CNY
Year-over-year change
+36.4%
4-year CAGR
+28.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How AAPG compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +36.4% is the 7th highest of 10, against a peer median of +59.1%.
  • Selling, general & admin amounts to 93.6% of revenue for AAPG, versus a peer median of 93.3%.
AAPG Competitors
Selling, General & Admin for AAPG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMRXImmuneering CorporationLTM Mar 2026$4.7B USD+29505.3%+3.5%—
AAPGAscentage Pharma Group InternationalFY2025CN¥522.67M CNY+36.4%+16.8%93.6%
ZLABZai Lab LimitedLTM Jun 2026$281.09M USD-1.1%+2.3%62.5%
NUVBNuvation Bio Inc.LTM Jun 2026$158.59M USD+32.6%+68.1%93.3%
VSTMVerastem, Inc.LTM Mar 2026$88.42M USD+83.1%+48.1%178.3%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$78.21M USD+57.0%+11.6%11.1%
TNGXTango Therapeutics, Inc.LTM Sep 2026$76.77M USD+79.2%+11.4%—
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$69.19M USD+65.4%+42.7%30.7%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$34.4M USD-16.4%-5.4%98.7%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$27.19M USD+59.1%+55.2%—
ANLAdlai Nortye Ltd.LTM Jun 2024$14.78M USD—-14.4%227.7%
Peer median (excluding AAPG) —+59.1%+11.5%93.3%

Competitors are the stored peer set for AAPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CNY
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue27.91M209.71M221.98M980.65M558.48M
Cost of Revenue3.33M22M30.54M29.09M131.73M
Gross Profit24.58M187.71M191.44M951.57M426.75M
Gross Margin88.1%89.5%86.2%97.0%76.4%
Research & Development766.49M743.1M706.97M947.25M1.08B
Selling, General & Admin191.26M328.02M376.46M383.12M522.67M
Operating Expenses957.75M1.04B1.06B1.32B1.61B
Depreciation & Amortization17.18M47.42M93.2M93.17M84.12M
EBITDA(798.34M)(786.97M)(743.61M)(237.63M)(1.1B)
EBITDA Margin-2860.4%-375.3%-335.0%-24.2%-196.1%
Operating Income(869.84M)(849.81M)(872.64M)(369.73M)(1.18B)
Operating Margin-3116.6%-405.2%-393.1%-37.7%-211.1%
Interest Income7.11M9.73M32.41M37.84M79.89M
Interest Expense16.73M52.79M96.06M64.46M52.6M
Other Income / Expenses37.59M(37.36M)(60.23M)(25.53M)(23.21M)
Income Before Tax(832.25M)(887.17M)(932.86M)(395.26M)(1.2B)
Pre-Tax Margin-2981.9%-423.0%-420.2%-40.3%-215.3%
Income Tax Expense(49.83M)(4.25M)(7.15M)10.43M6.75M
Net Income(782.42M)(882.92M)(925.64M)(405.43M)(1.21B)
Net Margin-2803.4%-421.0%-417.0%-41.3%-216.5%
EPS (Basic)(49.12)(53.60)(52.48)(5.36)(13.56)
EPS (Diluted)(49.12)(53.60)(52.48)(5.36)(13.56)
Weighted Avg Shares15.91M16.48M17.64M75.52M89.03M
Weighted Avg Shares (Diluted)15.91M16.48M17.64M75.52M89.03M

Ascentage Pharma Group International

NASDAQ:AAPG

Intrinsic Alpha fair value

Locked

Current Price

$13.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.